Rapidly screen for anti-inflammatory leads using Repligut® Planar
Inflammatory bowel diseases (IBD) are a major health concern worldwide
Inflammatory bowel diseases (IBD) are a major health concern worldwide, with an estimated 1.6 million cases in the US alone. While there are many treatments available, they are often ineffective and can cause harmful side effects.
A major reason successful IBD therapies remain elusive is that current model systems cannot replicate key mechanistic aspects of the epithelial inflammatory response in humans.
That’s why we developed InflammaScreen™ Services, a suite of pre-qualified, multiple readout assays using our flagship model RepliGut® Planar Transverse Colon. These assays are specifically designed to both speed up discovery and improve the human relevance of gastrointestinal inflammation-focused drug discovery.
Rapidly Screen for anti-inflammatory activities
Using InflammaScreen™ Services, you can:
1. Reliably evaluate the ability to augment or block intestinal epithelium response to proinflammatory cytokines using a pre-qualified assay with defined readouts.
Fully mature RepliGut® Planar models are first pre-treated with test articles followed by treatment with TNFa. Cultures are pre-treated with your compounds. Pro-inflammatory cytokine TNF-a is added to initiate damage. TEER measurements are taken at 24- and 48-hours post-treatment; LDH and IL8 measurements are taken at 48 hours post-treatment.
2. Quickly receive results from three independent biological outputs
(cytotoxicity, barrier integrity, pathway-dependent cytokine release)
3. Reveal powerful mechanistic and functional insights
for better downstream decision making
Download the interactive platemap
Learn more about InflammaScreen™ services from our interactive platemap. Click the button below to download an excel spreadsheet.
Ready to Go With Your Gut?
Contact us to learn more about RepliGut® Model Kits and Services.
Get in touch with us
Have a question?
Want to learn more about RepliGut® Systems? Send us a Message